Abstract:
This retrospective study involved the examination of 34 children aged 7 to 14
years suffering from nephrogenic sepsis. Detailed anamnesis data were collected, including physical
development indicators, general and biochemical blood tests, urinalysis, and stool analysis. Aim of
the study. The primary objective was to assess the clinical effectiveness of comprehensive therapy
using the drug Nefroton Kids in combating infections caused by the most common pathogens of
sepsis in children. Materials and methods of the study. The treatment protocol included the use of
Nefroton Kids as part of combination therapy for managing infections such as Escherichia coli (E. coli)
(responsible for approximately 60–80% of cases), Klebsiella spp., Proteus mirabilis, Staphylococcus
saprophyticus, Enterococcus faecalis, and Pseudomonas aeruginosa. Results. Clinical, laboratory,
and instrumental data indicated an improvement in the patients’ condition, with the recovery period
reduced by 2–5 days. Conclusion. Thus, the use of Nefroton Kids appears to be effective not only
in the treatment of kidney pathologies but also in preventing complications arising after nephrogenic
sepsis.
